Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|July 10, 2024

Concluding Remarks: Systemic Treatment Considerations for Atopic Dermatitis in Patients of Childbearing Potential

Author(s)Elizabeth Kiracofe, MD, FAAD, Jenny Murase, MD, FAAD

Looking to the future of atopic dermatitis treatment, Drs Kiracofe and Murase offer concluding remarks on current unmet needs, the benefits of treatment guidelines, and the importance of treating itch in patients who are or may become pregnant.

Episodes in this series

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 1 Unveiling Treatment Gaps: Expert Perspectives on the Undermanagement of Patients with Atopic Dermatitis and Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 2 Fostering Communication: Promoting Dialogue on Atopic Dermatitis Treatment Concerns in Patients of Childbearing Potential

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 3 Exploring Changes in Atopic Dermatitis Severity Across the Pregnancy Journey

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 4 Navigating Treatment Choices: Balancing Treatment Options for Childbearing-Age Patients

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 5 Insights on Transcription Binding in Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 6 Informed Decisions: Dialogue with Treatment-Naïve Pregnant Patients Regarding Systemic Atopic Dermatitis Treatment Options

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 7 Managing Atopic Dermatitis Treatment Escalation in Pregnancy: Considerations and Approaches

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 8 Urgent Need for Consensus on Systemic Treatments for Atopic Dermatitis in Childbearing-Age Populations

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 9 Considerations for Breastfeeding, Lactation, and Postpartum in Family Planning Patients with Atopic Dermatitis

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis

EP. 10 Concluding Remarks: Systemic Treatment Considerations for Atopic Dermatitis in Patients of Childbearing Potential

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

EP. 11 Ten Clinical Considerations to Manage AD in Pregnant Patients

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Phase 2 Data Highlight Roflumilast Cream in Infant AD

ByMaddi Hebebrand, MC, Associate Editor

February 2nd 2026

Kyowa Kirin Takes Full Control of Rocatinlimab Program

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Phase 2 TYK2 Inhibition Shows Promise in AD

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

ByMaddi Hebebrand, MC, Associate Editor

January 23rd 2026

Level Up Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD

ByMaddi Hebebrand, MC, Associate Editor

January 22nd 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Introducing Dermatology Times NP/PA Connect

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older